Warfarin: Comprehensive Drug Monograph

Pharmacokinetic Profile

Half-Life

~40 h (racemic, mean)
S-warfarin 21–43 h
R-warfarin 37–89 h

Metabolism

Hepatic — S-isomer via CYP2C9; R-isomer via CYP1A2 / 3A4

Protein Binding

~99% (albumin)

Bioavailability

Essentially complete (oral)

Volume of Distribution

~0.14 L/kg

Therapeutic Index

Narrow

Clinical Information

Drug Class

Vitamin K antagonist

Available Doses

1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg tablets

Route

Oral

Renal Adjustment

No fixed adjustment; titrate to INR

Hepatic Adjustment

Reduce dose; severe disease = contraindication

Pregnancy

Contraindicated (Category X) — narrow exception for mechanical valves

Lactation

Compatible — minimal milk transfer

Schedule / Legal

Rx only (non-controlled)

Black Box Warning

Yes — bleeding risk

Generic Available

Yes

Indications

Indication	Approved Population	Therapy Type	Status
Venous thromboembolism — DVT and pulmonary embolism, treatment and secondary prevention	Adults; pediatrics off-label	Monotherapy after parenteral overlap	FDA Approved
Atrial fibrillation — stroke and systemic embolism prevention	Adults with AF (valvular or non-valvular)	Monotherapy	FDA Approved
Mechanical heart valves — prevention of valve thrombosis and systemic embolism	Adults with prosthetic valves; pediatric off-label	Monotherapy (sole oral anticoagulant of choice)	FDA Approved
Post-myocardial infarction — reduction of recurrent MI, stroke, and systemic embolism	Adults after MI	Monotherapy or with low-dose aspirin (selected patients)	FDA Approved
Bioprosthetic mitral valve — first 3–6 months post-implant	Adults	Monotherapy, time-limited	FDA Approved

Warfarin remains the only oral anticoagulant with proven mortality benefit and FDA approval for mechanical heart valves and for valvular atrial fibrillation (rheumatic mitral stenosis). For non-valvular AF and for most VTE indications, direct oral anticoagulants (DOACs) are preferred first line per current AHA/ACC/HRS and CHEST guidance, with warfarin reserved for specific scenarios where DOACs are inappropriate or contraindicated.

Off-label uses

Antiphospholipid antibody syndrome (high-quality evidence): Long-term warfarin with INR target 2.0–3.0 is the standard of care for thrombotic APS; rivaroxaban is inferior in triple-positive disease (TRAPS trial).

Left ventricular thrombus after anterior MI (moderate-quality evidence): Typical course is 3–6 months with INR 2.0–3.0, then reassess by echocardiography.

Cerebral venous sinus thrombosis (moderate-quality evidence): Used for chronic-phase anticoagulation following acute heparin therapy; duration 3–12 months depending on provoking factors.

Heparin-induced thrombocytopenia after platelet recovery (low-quality evidence): Initiated only after platelets normalise and overlap with a non-heparin parenteral agent for ≥5 days.

Dose

Dosing

Warfarin dosing is governed by the international normalised ratio (INR) target for the indication, not by tablet strength. Initial doses are estimates; the maintenance dose is whatever achieves the target INR for that patient. Most adults stabilise on 2–10 mg daily, but the inter-patient range is wide. Begin with conservative induction in elderly, frail, low-BMI, malnourished, hepatic-impaired, or known CYP2C9 poor metaboliser patients.

Adult Dosing by Clinical Scenario

Clinical Scenario	Starting Dose	Maintenance Dose	Maximum Dose	Notes
Non-valvular atrial fibrillation — stroke prevention	2–5 mg PO daily × 2 days	2–10 mg PO daily (INR-titrated)	No fixed ceiling	Target INR 2.0–3.0 No parenteral bridge required for AF unless mechanical valve or recent stroke. Lower end of starting range for elderly, frail, low BMI
Acute VTE (DVT/PE) — initiation	5 mg PO daily × 2 days	2–10 mg PO daily (INR-titrated)	No fixed ceiling	Target INR 2.0–3.0 Overlap with parenteral anticoagulant ≥5 days AND until INR ≥2.0 for ≥24 h. Some VTE protocols start at 10 mg × 2 days in young, healthy outpatients
Mechanical aortic valve (current-generation bileaflet or single tilting-disk, no risk factors)	2–5 mg PO daily × 2 days	2–10 mg PO daily (INR-titrated)	No fixed ceiling	Target INR 2.5 (range 2.0–3.0); add low-dose aspirin per AHA/ACC Bridging is not required for elective procedures if no other thromboembolic risk factors
Mechanical mitral valve, OR mechanical aortic with thromboembolic risk factors, OR older-generation prosthesis	2–5 mg PO daily × 2 days	2–10 mg PO daily (INR-titrated)	No fixed ceiling	Target INR 3.0 (range 2.5–3.5); add low-dose aspirin Risk factors: AF, prior thromboembolism, LV dysfunction, hypercoagulable state, older-generation valve. Bridging recommended around invasive procedures
Antiphospholipid syndrome (thrombotic) — secondary prevention	2–5 mg PO daily	2–10 mg PO daily	No fixed ceiling	Target INR 2.0–3.0 (standard intensity) Higher intensity (INR 3.0–4.0) considered in recurrent thrombosis on therapeutic INR or arterial events
Bioprosthetic mitral valve — first 3–6 months	2–5 mg PO daily	2–10 mg PO daily	No fixed ceiling	Target INR 2.5 (range 2.0–3.0) × 3–6 months, then transition to aspirin Bioprosthetic aortic valves usually need only aspirin; warfarin reasonable in selected patients
LV thrombus after anterior MI	2–5 mg PO daily	2–10 mg PO daily	No fixed ceiling	Target INR 2.0–3.0 × 3–6 months; reassess with echo Evidence is weaker than for AF or mechanical valves; DOACs are an alternative
Bridging from heparin/LMWH	2–5 mg PO daily × 2 days	2–10 mg PO daily	No fixed ceiling	Continue parenteral agent ≥5 days AND until INR ≥2.0 for ≥24 h Stopping heparin too early before factor II depletion is a frequent error

Population-Specific Adjustments

Population	Starting Dose	Considerations
Elderly (≥75 y) or frail	2–3 mg PO daily	Slower metabolism, polypharmacy, fall risk; higher bleeding risk per HAS-BLED
Low body weight (<50 kg)	2.5–5 mg PO daily	Reduced lean mass and albumin; lower maintenance requirement
Mild-moderate hepatic impairment	2–3 mg PO daily	Reduced clotting factor synthesis; baseline INR may already be elevated; monitor LFTs
Severe hepatic impairment (Child-Pugh C)	Contraindicated — unpredictable response and excessive bleeding risk
Asian ancestry	2–3 mg PO daily	FDA label notes mean daily warfarin requirement of approximately 3.3 mg in Chinese outpatients (INR 2.0–2.5); higher prevalence of CYP2C9 and VKORC1 variants reduces dose requirements
Known CYP2C9 2/3 or VKORC1 -1639 G>A	2–3 mg PO daily	Pharmacogenomic-guided dosing reduces time to stable INR; consider warfarindosing.org calculator
Pediatric (off-label, specialist initiated)	0.2 mg/kg PO daily × 2 days	Then titrate; reduce starting dose by 50% if hepatic dysfunction or post-Fontan
Transition from a DOAC to warfarin	Overlap warfarin with the DOAC until INR is therapeutic; remember the DOAC may artefactually elevate INR — interpret cautiously and consider checking 24 h after last DOAC dose

Clinical pearl — induction strategy

The current FDA Coumadin label recommends an initial dose of 2–5 mg once daily without genotype information; 10 mg × 2 days remains an option in some protocols for younger, healthier outpatients with acute VTE. Whatever the chosen initial dose, large doses can cause an early dip in protein C (a natural anticoagulant) before factors II, IX, and X fall, creating a brief paradoxical hypercoagulable window — which is one rationale for parenteral overlap in acute VTE and for caution in protein C/S deficiency. Check the INR on day 3, then adjust by 10–20% increments. The full anticoagulant effect requires 5–7 days, so heparin bridging is essential in acute VTE and mechanical valve scenarios until INR has been ≥2.0 for at least 24 hours.

Pharmacology

Mechanism of Action

Warfarin is a racemic mixture of S- and R-enantiomers that inhibits vitamin K epoxide reductase complex 1 (VKORC1) in the liver. By blocking the regeneration of reduced vitamin K, warfarin starves the gamma-glutamyl carboxylase enzyme of its essential cofactor and prevents the post-translational gamma-carboxylation of vitamin K-dependent factors II (prothrombin), VII, IX, and X, as well as the natural anticoagulants protein C and protein S. The non-carboxylated proteins are released into the circulation but cannot bind calcium and are functionally inert.

Because circulating clotting factors must be cleared before the anticoagulant effect manifests, the INR begins to rise within 24–36 hours (driven by depletion of factor VII, half-life ~6 h) but full antithrombotic effect is delayed until prothrombin levels fall, requiring approximately 5–7 days. The S-enantiomer is two to five times more potent than the R-enantiomer and is preferentially metabolised by CYP2C9 — the enzyme responsible for the majority of clinically meaningful pharmacokinetic interactions.

ADME Profile

Parameter	Value	Clinical Implication
Absorption	Essentially complete oral absorption; Tmax ~4 h; food may delay but does not reduce extent of absorption	Take at the same time daily for steady absorption; no IV formulation routinely required
Distribution	Vd ~0.14 L/kg (small, mainly intravascular); ~99% albumin-bound	Hypoalbuminaemia or albumin-displacing drugs raise free fraction and bleeding risk; warfarin is not removed by dialysis
Metabolism	Hepatic; S-warfarin via CYP2C9 (major); R-warfarin via CYP1A2 and CYP3A4; minor contributions from CYP2C19, 2C8, 2C18	CYP2C9 2 and 3 alleles markedly reduce S-warfarin clearance and require lower doses; most major DDIs act through CYP2C9
Elimination	Inactive hydroxylated metabolites in urine (up to 92% of dose); <1% unchanged drug; effective t½ 20–60 h (mean ~40 h)	Steady state reached in ~5–7 days; renal impairment does not necessitate fixed dose adjustment

Side Effects

Bleeding dominates the warfarin adverse-effect profile and accounts for almost all hospitalisations and discontinuations. Annual rates depend on INR control (time in therapeutic range), age, comorbidity, and concomitant antiplatelet therapy. The rates below are pooled from pivotal AF and VTE trials in which warfarin was the comparator arm (RE-LY, ROCKET AF, ARISTOTLE, ENGAGE AF-TIMI 48).

≥10% Very Common

Adverse Effect	Incidence	Clinical Note
Easy bruising / ecchymoses	10–15%	Cosmetic, not a reason to stop; reassure unless spontaneous, large, or expanding
Minor bleeding (gums, nose, minor cuts)	10–15%/yr	Address with local pressure; consider INR check if recurrent

1–10% Common

Adverse Effect	Incidence	Clinical Note
Major bleeding (any site)	2.0–3.5%/yr	RE-LY warfarin arm 3.36%/yr; ARISTOTLE 3.09%/yr; ROCKET AF 3.4%/yr; lower in well-controlled VTE cohorts
GI bleeding	1–3%/yr	Most common single site; risk amplified by concurrent NSAIDs or antiplatelets
Hematuria	1–2%/yr	Often unmasks an underlying urological lesion — always investigate, do not attribute to warfarin alone
Epistaxis (significant)	1–4%/yr	Counsel on saline spray and humidification; check blood pressure if recurrent
Nausea, dyspepsia, anorexia	1–5%	Usually mild; take with food if intolerant
Alopecia (diffuse, reversible)	~1–3%	Onset weeks to months; resolves on discontinuation; rarely requires switching
Rash (non-specific)	1–3%	Distinguish from skin necrosis (painful, demarcated) — see Serious tier

Serious Serious Adverse Events

Adverse Effect	Estimated Frequency	Typical Onset	Required Action
Intracranial hemorrhage	0.3–0.8%/yr	Any time on therapy	Emergency reversal: 4-factor PCC + IV vitamin K 10 mg; neurosurgical consult; permanent reassessment of indication
Major non-CNS hemorrhage	2.0–3.5%/yr	Any time	Hold drug; reverse with PCC + IV vitamin K if life-threatening or INR >10; identify bleeding source
Warfarin-induced skin necrosis	<0.1%	Days 3–10 of therapy	Stop immediately; reverse with vitamin K; bridge with parenteral anticoagulant; investigate for protein C/S deficiency
Purple toe syndrome (cholesterol microembolisation)	Rare	Weeks 3–10	Stop warfarin; switch to alternative anticoagulant; vascular workup for atherosclerotic source
Calciphylaxis (calcific uraemic arteriolopathy)	Very rare	Months to years; mostly in dialysis patients	Discontinue; multidisciplinary management; sodium thiosulfate; switch anticoagulant strategy
Hepatitis / cholestatic liver injury	Rare	First weeks to months	Stop and assess LFTs; switch to alternative anticoagulant; usually reversible
Anaphylaxis / hypersensitivity	Very rare	Any time	Permanent discontinuation; switch class; emergency management of acute reaction
Embryopathy (warfarin syndrome) — first-trimester exposure	~5% if exposed weeks 6–12	Detected at fetal anomaly scan	Maternal-fetal medicine referral; teratogenic effect is dose-related; transition to LMWH preconceptionally

Discontinuation Discontinuation Rates

Adults — Long-term AF

~25–30% at 1 yr across pooled real-world cohorts

Top reasons: bleeding, monitoring burden, drug-interaction inconvenience, switch to a DOAC.

Pediatric (off-label use)

Limited data small registry cohorts only

Top reasons: dietary/lifestyle constraints, INR variability, parental preference for parenteral options or for switching to a DOAC where age-appropriate.

Reason for Discontinuation	Approximate Rate	Context
Bleeding event	3–5%/yr	Major bleed almost always prompts at least temporary cessation; resumption decision balances thrombotic vs. recurrent bleed risk
Switch to DOAC	10–20% over follow-up	Driven by patient preference and guideline shift toward DOACs in non-valvular AF and most VTE
Poor INR control / labile INR	5–10%	TTR <60% identifies patients unlikely to benefit; switch class rather than persist
Patient preference / monitoring burden	3–8%	Phlebotomy access, transportation, frequent dose changes; consider point-of-care INR self-testing
Hypersensitivity, hepatitis, skin necrosis	<1%	Permanent discontinuation; switch to alternative class

Management — supratherapeutic INR without bleeding

INR 4.5–10: Hold warfarin; routine vitamin K is not required; recheck INR in 24–48 h.

INR >10: Hold warfarin; give oral vitamin K 2.5–5 mg; recheck INR daily; resume at lower dose once INR is in range.

Any major bleeding (regardless of INR): Hold warfarin; 4-factor prothrombin complex concentrate (PCC) 25–50 IU/kg by indication-specific protocol PLUS IV vitamin K 5–10 mg; recheck INR 30 min and 6 h post-dose. FFP is an inferior reversal option and should be reserved for situations where PCC is unavailable.

Int

Drug Interactions

Warfarin has more clinically significant interactions than almost any other widely-prescribed drug. The dominant pathway is inhibition or induction of CYP2C9 (which metabolises the more potent S-enantiomer); secondary mechanisms include CYP1A2/CYP3A4 effects on R-warfarin, displacement from albumin, additive bleeding from antiplatelet or anticoagulant pharmacodynamics, disruption of vitamin K availability, and altered platelet or mucosal integrity. The list below covers the highest-yield interactions in primary and specialty care; consult a clinical interaction database before any new co-prescription.

Major Interactions

Major Amiodarone

MechanismPotent inhibition of CYP2C9 and CYP3A4; long half-life prolongs effect

EffectINR rises 1.5–2× over 1–3 weeks; bleeding risk doubles

ManagementEmpirically reduce warfarin by 30–50% at amiodarone start; check INR weekly × 4 weeks

FDA PI · Lexicomp

Major Fluconazole / Voriconazole / Miconazole

MechanismStrong CYP2C9 inhibition

EffectINR can rise within 2–4 days; reports of supratherapeutic INR >10 with topical miconazole

ManagementReduce warfarin 30–50% empirically; switch to itraconazole or terbinafine where clinically appropriate

FDA PI · Lexicomp

Major Trimethoprim-sulfamethoxazole

MechanismCYP2C9 inhibition + albumin displacement

Effect2–3× higher hospitalisation for upper-GI bleeding in elderly

ManagementUse alternative antibiotic when possible; if necessary, reduce warfarin 25–50% and check INR at day 5–7

Lexicomp · CMAJ 2010

Major Metronidazole

MechanismCYP2C9 inhibition

EffectINR may double within a week

ManagementReduce warfarin 30–50%; check INR within 5–7 days; resume usual dose at antibiotic completion

FDA PI · Lexicomp

Major Rifampin / Rifabutin

MechanismPotent CYP2C9 / CYP3A4 induction

EffectINR drops over 1–3 weeks; warfarin requirement may double; thrombotic risk on stopping rifampin

ManagementAnticipate dose increases; check INR weekly during induction and again 2–4 weeks after rifampin discontinuation

FDA PI · Lexicomp

Major NSAIDs (ibuprofen, naproxen, diclofenac, ketorolac)

MechanismPlatelet inhibition + gastric mucosal injury; some CYP2C9 effect

EffectUp to 4× higher GI bleeding risk; INR effect minor but bleed risk substantial

ManagementAvoid combination; use acetaminophen or topical NSAIDs; if essential, add PPI and short course only

FDA PI · Holbrook 2005

Major Aspirin (any dose) / Clopidogrel / Prasugrel / Ticagrelor

MechanismAdditive antiplatelet effect on top of warfarin anticoagulation

Effect2–3× higher major bleeding; triple therapy adds further risk

ManagementUse only with documented indication (mechanical valve, recent ACS/PCI); shorten duration of dual or triple therapy per AHA/ACC

FDA PI · ACC/AHA

Major Phenytoin / Carbamazepine / Phenobarbital

MechanismCYP2C9 / CYP3A4 induction (chronic); transient inhibition at initiation

EffectBiphasic — INR may rise then fall; phenytoin levels also affected by warfarin

ManagementFrequent INR checks (weekly × 4); consider non-enzyme-inducing antiseizure medication when possible

FDA PI · Lexicomp

Major St John’s wort (Hypericum)

MechanismCYP3A4 and CYP2C9 induction

EffectINR falls; thromboembolic events reported on initiation

ManagementAvoid; counsel patients on herbal-product disclosure; check INR if recently started or stopped

FDA PI · Cochrane

Major Vitamin K (oral, IV, or in TPN)

MechanismDirect pharmacodynamic antagonism (replaces reduced vitamin K)

EffectINR drops within hours; thromboembolic risk if reversal is overshot

ManagementCounsel on consistent dietary vitamin K intake; avoid green-leafy bingeing or starvation; specify doses for reversal carefully

FDA PI · CHEST

Moderate Interactions

Moderate SSRIs / SNRIs (especially fluoxetine, paroxetine, sertraline, duloxetine)

MechanismPlatelet serotonin depletion impairs primary hemostasis; some CYP2C9 inhibition with fluoxetine

Effect~1.5–2× increase in upper-GI bleeding

ManagementUse lowest effective antidepressant dose; consider mirtazapine alternative; add PPI in high-risk patients

Lexicomp · BMJ

Moderate Acetaminophen (high dose, prolonged)

MechanismInhibition of vitamin K cycle by NAPQI metabolite (theory); dose-dependent

EffectINR rise of 0.5–1.0 with >2 g/day for ≥7 days

ManagementLimit chronic dosing to ≤2 g/day where possible; check INR a few days into a high-dose course

JAMA · Lexicomp

Moderate Statins (especially simvastatin, rosuvastatin, fluvastatin)

MechanismVariable CYP and protein-binding effects; fluvastatin is the strongest CYP2C9 inhibitor in class

EffectModest INR elevation (~0.3–0.5)

ManagementCheck INR 1 week after statin start or dose change; atorvastatin has the smallest interaction

Lexicomp

Moderate Levothyroxine

MechanismPharmacodynamic — thyroid hormone increases clotting factor catabolism, enhancing warfarin effect

EffectINR rises as patient becomes euthyroid from hypothyroid

ManagementRecheck INR within 2–4 weeks of any thyroid status change or dose adjustment

Lexicomp

Moderate Tramadol

MechanismMechanism unclear; reports of INR elevation and bleeding

EffectVariable INR rise; case reports of major bleeding

ManagementPrefer scheduled acetaminophen or short-course oxycodone; recheck INR within a week

Case reports · Lexicomp

Moderate Cranberry juice (high intake)

MechanismPossible mild CYP2C9 inhibition; evidence inconsistent

EffectCase reports of INR elevation with large daily volumes

ManagementLimit to ≤1 cup/day; check INR if intake suddenly changes

Case reports

Minor / Notable Interactions

Minor Proton pump inhibitors (omeprazole, esomeprazole)

MechanismMild CYP2C19 / CYP2C9 effect

EffectSmall INR rise (~0.2)

ManagementContinue PPI when indicated for GI protection; routine INR check on initiation

Lexicomp

Minor Cimetidine

MechanismMulti-CYP inhibitor

EffectINR rise of 0.3–0.7

ManagementSwitch to famotidine or a PPI

Lexicomp

Mon

Monitoring

Monitoring is what makes warfarin clinically usable — a fixed dose without INR feedback is unsafe. Aim for time in therapeutic range (TTR) ≥65%; below 60% the bleeding–thrombosis trade-off is no better than aspirin and a switch to an alternative anticoagulant should be considered.

INR Day 3, then every 2–3 days until in range; weekly × 1–2 weeks; then monthly when stable
Routine Cornerstone of monitoring. Confirm target by indication (2.0–3.0 vs 2.5–3.5). Recheck within 5–7 days of any new interacting medication, illness, or significant dietary change. TTR is the strongest predictor of outcomes — calculate quarterly using the Rosendaal method.
CBC (Hgb, platelets) Baseline, then at 1 month, then per clinical concern
Routine Detects occult blood loss and confirms platelet adequacy. A drop in Hgb without obvious bleeding source warrants GI evaluation.
Liver function tests Baseline, then per clinical concern
Trigger-based Severe hepatic disease is a contraindication. Recheck if new symptoms, jaundice, or unexpected INR elevation suggest hepatocellular dysfunction.
Renal function (creatinine, eGFR) Baseline, then annually
Routine Although warfarin itself does not require renal dose adjustment, declining function changes the bleeding-risk profile (HAS-BLED), and worsening eGFR may prompt switch decisions.
Bleeding signs Every visit
Routine Direct questioning about bruising, gum bleeding, hematuria, melena, hematemesis, headache, or unexplained dyspnoea. Document and act on any new findings — do not wait for the next routine INR.
Bleeding risk score Baseline, then annually
Routine HAS-BLED (US/ESC tradition) or ORBIT (preferred by NICE NG196) score; high score flags higher bleeding risk and identifies modifiable factors (uncontrolled BP, NSAID use, alcohol). The score should not be used alone to deny anticoagulation in patients with a clear thrombotic indication.
Time in therapeutic range Quarterly review
Routine Persistent TTR <60% is a strong indication to switch to a DOAC where eligible (i.e. not mechanical valve, not severe rheumatic mitral stenosis).
Pharmacogenomic testing Once, before initiation (where available)
Trigger-based CYP2C9 and VKORC1 genotyping refines starting dose. Most valuable in patients with prior unstable INR, very high or very low dose requirements, or family history of warfarin sensitivity.
Pregnancy testing Before initiation in women of childbearing potential; whenever pregnancy suspected
Trigger-based First-trimester exposure causes warfarin embryopathy; counsel on contraception and switch to LMWH preconceptionally where pregnancy is planned.

Contraindications & Cautions

FDA Boxed Warning Bleeding risk

Warfarin can cause major or fatal bleeding. Risk is highest in the first month of therapy and is amplified by elevated INR (especially >4.5), age ≥65, history of GI bleed, severe or uncontrolled hypertension, prior stroke, anaemia, malignancy, trauma, renal impairment, drug interactions (notably NSAIDs and antiplatelets), and CYP2C9 or VKORC1 polymorphisms. Frequent INR monitoring is required throughout therapy. Educate every patient on early signs of bleeding and on the immediate steps to take if they occur. Drug-specific reversal with 4-factor prothrombin complex concentrate plus IV vitamin K is the standard of care for major haemorrhage.

Absolute Contraindications

Pregnancy (Category X) — except in mechanical heart valve recipients where second-trimester warfarin may be considered after explicit counselling and shared decision-making
Active major bleeding — GI, intracranial, or other clinically significant haemorrhage
Hemorrhagic tendencies or blood dyscrasias
Recent CNS surgery, head trauma, or hemorrhagic stroke
Recent or contemplated eye surgery (other than minor lens surgery, after risk-benefit assessment)
Bacterial endocarditis
Pericarditis or pericardial effusion
Cerebral aneurysm or dissecting aorta
Threatened abortion, eclampsia, or pre-eclampsia
Malignant or severe uncontrolled hypertension (e.g. BP >180/110 mmHg sustained)
Severe hepatic disease (Child-Pugh C; oesophageal varices)
Severe thrombocytopenia (platelets <50 × 10⁹/L) without a clear reversible cause
Documented hypersensitivity to warfarin or any component
Inability to monitor INR reliably, or unsupervised patients with high likelihood of non-adherence
Spinal puncture or other diagnostic/therapeutic procedure with potential for uncontrollable bleeding; major regional or lumbar block anaesthesia while anticoagulated

Relative Contraindications (Specialist Input Recommended)

Recent major surgery — coordinate timing with the surgical team
Inherited bleeding disorder (von Willebrand disease, mild haemophilia)
Frequent falls in older adults with cognitive impairment and no caregiver oversight — modelling suggests warfarin remains net beneficial in most fall-prone older adults, but very frequent injurious falls combined with poor supervision shift the balance; use HAS-BLED or ORBIT score and shared decision-making
Severe alcohol use disorder — labile INR and trauma risk
Prior warfarin-induced skin necrosis — re-challenge should be avoided unless no alternative
Heparin-induced thrombocytopenia in the acute phase — defer warfarin until platelets recover and a non-heparin parenteral overlap is established
Pregnancy with mechanical mitral valve — multidisciplinary obstetric/cardiology input mandatory
Active malignancy — generally favour LMWH or DOAC unless mechanical valve or APS

Use with Caution

Elderly (≥75 y) — start low, monitor often, deprescribe interacting drugs
Mild-to-moderate hepatic impairment — reduced clotting factor synthesis
Renal impairment — bleeding risk rises as eGFR falls; reassess strategy
Hyperthyroidism / hypothyroidism — INR shifts as thyroid status changes
Heart failure — hepatic congestion can amplify warfarin effect
Known CYP2C9 *2/*3 or VKORC1 -1639 G>A polymorphism — start at the low end of the dose range
Concurrent use of any interacting medication (see Interactions section) — additive monitoring required

Patient Counselling

Purpose of Therapy

Patients should leave the consultation knowing the specific reason they are taking warfarin (preventing stroke in atrial fibrillation, preventing valve thrombosis, treating a clot in the leg or lung, etc.) and the specific INR range they are aiming for. Anchor the conversation on this single sentence: warfarin thins the blood just enough to prevent dangerous clots without causing serious bleeding — and the INR is how we make sure the dose is right for you.

How to Take

Take warfarin once daily, at the same time each day, with or without food. Use the same brand consistently if possible — generic-to-generic switching can shift the INR. Do not double a missed dose: if a dose is missed and remembered within a few hours, take it; if more than half a day has passed, skip it and resume the regular schedule the next day. Bring the medication bottle, the dosing diary, and the most recent INR card to every appointment.

Bleeding warning signs

Tell patient Some bruising and minor gum or nose bleeding is common. Pressure for 10 minutes usually stops minor bleeds. Most bruises are harmless.

Call prescriber If bleeding does not stop after 15 minutes, or if there is blood in urine or stool (red or black), vomiting blood or coffee-ground material, severe headache, sudden weakness or vision change, large new bruises without injury, or any uncontrolled bleeding — go to the emergency department.

Dietary vitamin K consistency

Tell patient Green leafy vegetables (spinach, kale, broccoli, brussels sprouts, lettuce) are healthy and should not be avoided. The goal is consistency week to week, not avoidance. Eat the same general amount each week.

Call prescriber If starting a new diet, becoming vegetarian, fasting (e.g. Ramadan), or markedly increasing or decreasing leafy greens for any reason — request an INR check within 1–2 weeks.

INR monitoring schedule

Tell patient The INR blood test tells us the dose is right. It is checked frequently at first, then every 4–6 weeks once stable. Keep a written INR log or use the practice’s anticoagulation card.

Call prescriber If an INR appointment is missed, if the INR was very high or very low at the last test, or if it has been more than 6 weeks since the last check.

New medications and OTC products

Tell patient Always ask before starting any new prescription, over-the-counter medicine, vitamin, or herbal supplement. Antibiotics, antifungals, ibuprofen, naproxen, fish oil, cranberry, garlic, ginkgo, and St John’s wort are common culprits. Acetaminophen is the safer first-choice painkiller — limit to 2 g per day for ongoing use.

Call prescriber Whenever a different doctor or dentist prescribes anything new, before starting any antibiotic course, and before any planned procedure.

Pregnancy and contraception

Tell patient Warfarin can cause serious harm to a developing baby, especially in the first three months. Use reliable contraception throughout treatment. If pregnancy is planned, an alternative blood thinner can be arranged in advance.

Call prescriber Immediately if pregnancy is suspected or confirmed, or before stopping any contraceptive method. Breastfeeding while on warfarin is generally safe — discuss before delivery.

Alcohol

Tell patient Light, regular alcohol intake (1–2 drinks/day) is usually safe. Binge drinking destabilises the INR and increases fall and bleeding risk.

Call prescriber If alcohol intake suddenly increases or decreases, or if cutting back from heavier drinking — schedule an INR check.

Falls, trauma, and procedures

Tell patient Carry a medical alert card or wristband stating warfarin use. Inform every dentist, surgeon, and emergency clinician. Plan ahead for procedures — many can be done without stopping warfarin if INR is <3.0.

Call prescriber After any head injury (even if feeling well), any fall with significant bruising, or before any planned surgery, dental extraction, colonoscopy, or injection.

Travel and lifestyle changes

Tell patient Keep medication in carry-on luggage. Carry the most recent INR result. For long trips, plan an INR check before leaving and identify a clinic at the destination if travel exceeds 4–6 weeks.

Call prescriber Before extended travel, before fasting periods (Ramadan, surgical fast), or with any major lifestyle change (illness, hospitalisation, new exercise programme).

Ref

Sources

Regulatory (Prescribing Information / SmPC)

Bristol-Myers Squibb. Coumadin (warfarin sodium) — US Prescribing Information. DailyMed (FDA). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb13533a-9eb3-44ca-a09c-4d4ca9be6f48 Authoritative US label — boxed warning, indications, dosing framework, and risk factors for bleeding.
Electronic Medicines Compendium. Warfarin tablets — UK SmPC. https://www.medicines.org.uk/emc/product/834 UK summary of product characteristics; complements the FDA label with European prescribing detail.

Key Clinical Trials

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY). N Engl J Med. 2009;361:1139–1151. doi:10.1056/NEJMoa0905561 Pivotal AF trial in which warfarin (target INR 2.0–3.0) was the comparator arm — source of contemporary major-bleeding rates.
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE). N Engl J Med. 2011;365:981–992. doi:10.1056/NEJMoa1107039 Provides high-quality contemporary warfarin major-bleeding and ICH event rates in over 9,000 warfarin-treated patients.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF). N Engl J Med. 2011;365:883–891. doi:10.1056/NEJMoa1009638 Warfarin TTR and bleeding outcomes in a higher-risk AF population — informs real-world expectations.
Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome (TRAPS). Blood. 2018;132:1365–1371. doi:10.1182/blood-2018-04-848333 Stopped early for excess thrombosis on rivaroxaban; supports continued warfarin preference in triple-positive APS.

Guidelines

Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149(1):e1–e156. doi:10.1161/CIR.0000000000001193 Defines current role of warfarin in valvular AF and indications where DOACs are preferred.
Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545–e608. doi:10.1016/j.chest.2021.07.055 Latest full-length CHEST VTE guidance — when to choose warfarin over DOACs, duration of therapy, and bridging principles.
Stevens SM, Woller SC, Baumann Kreuziger L, et al. Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012–2021. Chest. 2024;166(2):388–404. doi:10.1016/j.chest.2024.03.003 Most recent CHEST consolidation of currently relevant VTE guidance statements; complements the 2021 update.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25–e197. doi:10.1016/j.jacc.2020.11.018 Provides INR targets for mechanical aortic vs mitral valves and bioprosthetic valve recommendations.
Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314–3414. doi:10.1093/eurheartj/ehae176 Current European AF guidance — updates HAS-BLED to ORBIT for bleeding risk, introduces the AF-CARE pathway, and outlines warfarin’s continued role in valvular AF.
National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management — NG196. 2021. https://www.nice.org.uk/guidance/ng196 UK national framework for warfarin use, TTR thresholds, and switching to DOACs.

Mechanistic / Basic Science

Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. ACCP Guidelines. Chest. 2012;141(2 Suppl):e44S–e88S. doi:10.1378/chest.11-2292 Foundational mechanistic and clinical reference for vitamin K antagonist pharmacology and management.
Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–1106. doi:10.1001/archinte.165.10.1095 Most-cited synthesis of warfarin drug-drug and drug-food interactions; underpins many of the major and moderate ratings.

Pharmacokinetics / Special Populations

Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397–404. doi:10.1002/cpt.668 Practical CYP2C9 / VKORC1 / CYP4F2-guided dose-prediction algorithm with downloadable clinical tool.
Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107(12):1692–1711. doi:10.1161/01.CIR.0000063575.17904.4E Classic AHA/ACC reference on initiation, monitoring, and reversal — still cited in current guidelines.
Chai-Adisaksopha C, Hillis C, Siegal DM, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal: a systematic review and meta-analysis. Thromb Haemost. 2016;116(5):879–890. doi:10.1160/TH16-04-0266 Demonstrates faster INR correction and lower mortality with 4F-PCC vs FFP — basis for current reversal protocols.